| Scalable stirred-suspension bioreactor culture of human pluripotent stem cells DE Kehoe, D Jing, LT Lock, ES Tzanakakis Tissue Engineering Part A 16 (2), 405-421, 2010 | 344 | 2010 |
| Expansion and differentiation of human embryonic stem cells to endoderm progeny in a microcarrier stirred-suspension culture LT Lock, ES Tzanakakis Tissue Engineering Part A 15 (8), 2051-2063, 2009 | 229 | 2009 |
| Stem/progenitor cell sources of insulin-producing cells for the treatment of diabetes LT Lock, ES Tzanakakis Tissue engineering 13 (7), 1399-1412, 2007 | 117 | 2007 |
| Standardized biosynthesis of flavan-3-ols with effects on pancreatic beta-cell insulin secretion JA Chemler, LT Lock, MAG Koffas, ES Tzanakakis Applied Microbiology and Biotechnology 77, 797-807, 2007 | 97 | 2007 |
| Peak MSC—are we there yet? TR Olsen, KS Ng, LT Lock, T Ahsan, JA Rowley Frontiers in medicine 5, 178, 2018 | 94 | 2018 |
| Downstream technology landscape for large-scale therapeutic cell processing J Pattasseril, H Varadaraju, L Lock, JA Rowley Bioprocess Int 11 (3), 38-47, 2013 | 65 | 2013 |
| Propagation of embryonic stem cells in stirred suspension without serum DE Kehoe, LT Lock, A Parikh, ES Tzanakakis Biotechnology progress 24 (6), 1342-1352, 2008 | 62 | 2008 |
| Pseudoislets in stirred-suspension culture exhibit enhanced cell survival, propagation and insulin secretion LT Lock, SG Laychock, ES Tzanakakis Journal of biotechnology 151 (3), 278-286, 2011 | 42 | 2011 |
| Bioreactor parameters for microcarrier-based human MSC expansion under xeno-free conditions in a vertical-wheel system J Lembong, R Kirian, JD Takacs, TR Olsen, LT Lock, JA Rowley, T Ahsan Bioengineering 7 (3), 73, 2020 | 40 | 2020 |
| Ready-to-print cells and integrated devices JA Rowley, LT Lock US Patent 11,058,106, 2021 | 13 | 2021 |
| Scalable process for therapeutic cell concentration and residual clearance J Rowley, J Pattasseril, LT Lock US Patent 10,385,307, 2019 | 8 | 2019 |
| Cryopreserved hMSCs maintain comparable in vitro functional activity compared to fresh hMSCs I Farance, LT Lock, P Baraniak, JA Rowley Cytotherapy 17 (6), S67-S68, 2015 | 4 | 2015 |
| Scalable production of pancreatic islet progenitors for diabetes cell therapies. LT Lock, ES Tzanakakis The Medical Journal of Malaysia 63, 5-6, 2008 | 4 | 2008 |
| Scaling up: how manufacturing sciences will dictate the future of cell therapy TR Olsen, LT Lock, JA Rowley REGENERATIVE MEDICINE 11 (8), S15-S18, 2016 | 3 | 2016 |
| The effect of cryomedia selection and transient warming events on post-cryopreservation human MSC function BJ Hawkins, A Abazari, LT Lock, T Ahsan, JA Rowley, J Fink, AJ Mathew Cytotherapy 20 (5), S40, 2018 | 2 | 2018 |
| Rapid and economic generation of consistent hMSC spheroids for macroscopic tissue biofabrication and therapeutic applications LT Lock, I Farance, P Baraniak, AC Tsai, T Ma, JA Rowley Cytotherapy 17 (6), S77, 2015 | 2 | 2015 |
| A xeno-free fed-batch microcarrier suspension bioreactor system for the scalable and economic expansion of hBM-MSCs TR Olsen, R Kirian, L Lock, JA Rowley Cytotherapy 20 (5), S48, 2018 | 1 | 2018 |
| Rapid and robust large-scale expansion of high quality human mesenchymal stem cells for use in regenerative medicine applications D Splan, L Lock, JA Rowley, MS Szczypka Cytotherapy 19 (5), S146, 2017 | 1 | 2017 |
| Derivation of heart cell progeny from human pluripotent stem cells D Jing, LT Lock, ES Tzanakakis ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 239, 2010 | 1 | 2010 |
| Methods and compositions related to extracellular material derived from hypertonic cell solutions JA Rowley, LT Lock, P RAVISHANKAR US Patent App. 17/055,276, 2021 | | 2021 |
